In November 2023, the FDA announced an investigation of CAR T-cell therapy based on several reported secondary T-cell malignancies.
Layla Sakr, 2024 PharmD Candidate
Advertisement
Articles by Layla Sakr, 2024 PharmD Candidate
Advertisement
Latest Updated Articles
Understanding the Implications of the FDA’s New Boxed Warning for CAR T-Cell TherapyPublished: February 7th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
2
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
3
Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health
4
New Data Show Elinzanetant Is a Safe, Well-Tolerated Non-Hormonal Therapy for Menopausal Vasomotor Symptoms
5
